Pharvaris (9EN) AI Stock Analysis

Pharvaris

(Frankfurt:9EN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Phase 3 efficacy and regulatory progressStrong Phase 3 prophylaxis results, combined with active FDA and EMA review, materially improve the credibility of deucrictibant as a future commercial product. The oral formulation and consistent efficacy support differentiation in HAE and create a clearer path toward potential launches.

Negative Factors

Pre-revenue business modelPharvaris has not yet generated product revenue, so its operating model remains dependent on successful clinical development, regulatory approvals, and eventual commercialization. Until those milestones occur, there is no established revenue base to offset development costs or validate recurring demand.

Pharvaris (9EN) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 2.34B
Dividend Yield: ―
Average Volume (3M): 132
Price to Earnings (P/E): -11.1
Beta (1Y): 0.57
Revenue Growth: ―
EPS Growth: 15.43%
Country: Germany
Employees: 148
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Pharvaris Business Overview & Revenue Model

Company Description

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a...

Pharvaris Risk Analysis

Pharvaris disclosed 82 risk factors in its most recent earnings report. Pharvaris reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.Our articles of association designate specific courts as the exclusive forum for certain litigation that may be initiated by our shareholders, which could limit our shareholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.Q4, 2023

2.to successfully commercialize our product candidates, or experience significant delays in doing so, our business, financial condition, results of operations and prospects would be materially adversely affected.Q4, 2023

Pharvaris Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:9EN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAR	65Neutral	$864.10M	34.56	8.96%	―	6.67%	2242.07%
BCRX	57Neutral	$2.16B	-5.89	101.55%	―	68.72%	-737.08%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OMER	48Neutral	$1.33B	9.65	-109.40%	―	―	―
KRSA	47Neutral	$1.37B	-2.50	-87.96%	―	-12.60%	-126.24%

* Healthcare Sector Average

Performance Comparison

DE:9EN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:9EN	Pharvaris N.V.	29.65	10.45	54.43%
BCRX	BioCryst Pharmaceuticals	8.47	1.61	23.47%
OMER	Omeros Corporation	18.44	11.27	157.18%
KRSA	Korsana Biosciences, Inc.	30.14	17.12	131.49%
PHAR	Pharming Group Nv	12.23	-1.09	-8.18%
ADRX	ADARx Pharmaceuticals, Inc.	17.00	-2.35	-12.14%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Pharvaris AI Stock Analysis